Loading…
Indivior Pharmaceuticals, Inc. is projected to rise to $56.09 by 2027, a +51% move from its current price of $37.11. INDV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $36.46 | $37.14 | $37.82 | +0.07% |
| May 30 | $36.22 | $37.16 | $38.14 | +0.15% |
| May 31 | $36.03 | $37.19 | $38.39 | +0.22% |
| Jun 1 | $35.88 | $37.22 | $38.61 | +0.30% |
| Jun 2 | $35.75 | $37.25 | $38.80 | +0.37% |
| Jun 3 | $35.64 | $37.28 | $38.98 | +0.45% |
| Jun 4 | $35.54 | $37.30 | $39.15 | +0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $35.54 | $37.30 | $39.15 | +0.52% |
| Week 2 | $35.01 | $37.50 | $40.16 | +1.04% |
| Week 3 | $34.66 | $37.69 | $40.99 | +1.57% |
| Week 4 | $34.39 | $37.89 | $41.74 | +2.09% |
| Week 5 | $34.17 | $38.08 | $42.44 | +2.63% |
| Week 6 | $34.00 | $38.28 | $43.10 | +3.16% |
| Week 7 | $33.85 | $38.48 | $43.74 | +3.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
The company was formerly known as Indivior PLC and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
INDV is currently trading at $37.53 with a market cap of $4.44B, and it ranks 1423 by market capitalization.
The near-term forecast for 2026 shows a min of $28.78, an avg of $37.53, and a max of $53.19, with an ROI of 0 and sentiment Neutral.
Looking further ahead, the forecast path suggests continued upside, with 2027 avg $56.57 and 2030 avg $88.88, followed by 2040 avg $291.16 and 2050 avg $572.71, all carrying a bullish sentiment for the longer horizon.
A major floor 26.4% below — a decisive break under it would weaken the trend.
The nearest floor, 15.1% below — buyers have tended to step in here.
The nearest ceiling, 9.4% above — a clean break opens room to run.
A major ceiling 22.6% above — clearing it would confirm fresh momentum.
Key INDV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INDV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.50 | Sell | $37.41 | Sell |
| MA 10 | $37.40 | Sell | $37.48 | Sell |
| MA 20 | $37.90 | Sell | $37.01 | Buy |
| MA 50 | $33.95 | Buy | $35.30 | Buy |
| MA 100 | $33.84 | Buy | $33.67 | Buy |
| MA 200 | $30.96 | Buy | $30.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.96 | Neutral |
| Stoch RSI (14) | 5.16 | Buy |
| CCI (20) | -49.72 | Neutral |
| Williams %R (14) | -81.37 | Info |
| MACD (12,26,9) | -0.32 | Sell |
| ROC (12) | -6.05 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 18.63 | Buy |
| TRIX (15) | 0.53 | Buy |
| Awesome (5,34) | 1.76 | Buy |
| Ultimate (7,14,28) | 48.60 | Neutral |
| Momentum (10) | -1.17 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 37.64 | Sell |
| ADX (14) | 21.63 | Buy |
| ATR (14) | 0.57 | Info |
The 30-day technical picture is bullish, with RSI14 at 60.
The moving averages show the stock trading above the SMA50 of $33.69 and above the SMA200 of $30.80, indicating an upward bias. Key levels to watch are support at $31.51 and resistance at $40.61, framing a clear upside path.
The 30-day price range runs from a low of $33.13 to a high of $42.51, highlighting a constructive near-term range-bound tilt with room to test the resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.78 | $37.11 | $52.42 | 0% | Neutral | |
| $45.82 | $56.09 | $71.87 | +51% | Bullish | |
| $56.04 | $69.86 | $91.85 | +88% | Bullish | |
| $63.38 | $80.19 | $107.63 | +116% | Bullish | |
| $69.64 | $89.29 | $121.95 | +141% | Bullish | |
| $79.08 | $102.62 | $142.35 | +177% | Bullish | |
| $85.84 | $112.64 | $158.45 | +204% | Bullish | |
| $100.09 | $132.71 | $189.06 | +258% | Bullish | |
| $123.41 | $165.25 | $238.22 | +345% | Bullish | |
| $133.78 | $180.82 | $263.54 | +387% | Bullish | |
| $214.11 | $301.78 | $460.79 | +713% | Bullish | |
| $392.59 | $593.36 | $970.90 | +15.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $28.78 | $37.11 | $43.63 | +0.00% |
| June 2026 | $33.48 | $39.06 | $46.45 | +5.24% |
| July 2026 | $33.84 | $39.70 | $47.66 | +1.65% |
| August 2026 | $33.49 | $39.47 | $47.73 | -0.59% |
| September 2026 | $34.22 | $40.48 | $49.23 | +2.55% |
| October 2026 | $35.26 | $41.85 | $51.18 | +3.40% |
| November 2026 | $35.23 | $41.94 | $51.53 | +0.21% |
| December 2026 | $35.57 | $42.47 | $52.42 | +1.28% |
Click any year to see its month-by-month INDV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect INDV to range from $28.78 to $52.42 through 2026. The $37.11 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The INDV price prediction for 2027 points to an average of $56.09 (low $45.82, high $71.87) — a potential gain of +51% on today's $37.11. Buyers look set to stay in control over this stretch.
In 2028, INDV is projected to trade between $56.04 and $91.85, averaging $69.86 — a potential gain of +88% from today's $37.11. That is up +25% on the projected 2027 average. Momentum favours further upside here.
Indivior Pharmaceuticals, Inc.'s 2029 outlook centres on $80.19, within a $63.38 to $107.63 range. That is up +15% on the projected 2028 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, INDV could reach as high as $121.95, with a base case around $89.29 and support toward $69.64 — roughly +141% from $37.11. Momentum favours further upside here.
Expect INDV to range from $79.08 to $142.35 through 2031. The $102.62 average target implies a +177% move from current prices. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The INDV price prediction for 2032 points to an average of $112.64 (low $85.84, high $158.45) — a potential gain of +204% on today's $37.11. Momentum favours further upside here.
In 2033, INDV is projected to trade between $100.09 and $189.06, averaging $132.71 — a potential gain of +258% from today's $37.11. That is up +18% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Indivior Pharmaceuticals, Inc.'s 2034 outlook centres on $165.25, within a $123.41 to $238.22 range. That is up +25% on the projected 2033 average. That marks a +345% change versus current levels. Momentum favours further upside here.
By 2035, INDV could reach as high as $263.54, with a base case around $180.82 and support toward $133.78 — roughly +387% from $37.11. Buyers look set to stay in control over this stretch.
Expect INDV to range from $214.11 to $460.79 through 2040. The $301.78 average target implies a +713% move from current prices. That is up +67% on the projected 2035 average. Momentum favours further upside here.
The INDV price prediction for 2050 points to an average of $593.36 (low $392.59, high $970.90) — a potential gain of +15.0x on today's $37.11. Buyers look set to stay in control over this stretch.
Investing $1,000 in INDV today (≈ 26.946915 INDV) could be worth
$15,989.34
+$14,989.34 (+1499%) by 2050 · US Dollar
Based on the average projected INDV price of $593.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INDVwould be worth at today's price.
$1,000 invested in INDV on May 27, 2025 (≈ 84.566598 INDV) would be worth
$3,138.27
+$2,138.27 (+213.8%) today · 3.14× · US Dollar
Based on a INDV entry price of $11.82 vs. today's $37.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.59 | $987.23 | -1.3% |
| 1 month ago | $34.31 | $1,081.61 | +8.2% |
| 3 months ago | $33.71 | $1,100.86 | +10.1% |
| 6 months ago | $33.6 | $1,104.46 | +10.4% |
| 1 year ago | $11.82 | $3,138.27 | +213.8% |
| All time (5.0y) ago | $10.5 | $3,534.29 | +253.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INDV forecast.
Our base-case forecast reaches $74.00 around 2029.
Implied market cap at $74.00: $8.75B
Over the multi-year horizon, the forecast portrays a strong upward trajectory. The 2026 avg is $37.53 with a neutral sentiment, and the path gains momentum in subsequent years, culminating in 2030 avg $88.88 and 2040 avg $291.16, followed by 2050 avg $572.71, all with bullish sentiment.
The longer-term forecast includes notable upside in years like 2030 (avg $88.88; ROI 136.8), 2040 (avg $291.16; ROI 675.8), and 2050 (avg $572.71; ROI 1426). This ascent is supported by a diversified buprenorphine-based portfolio and development programs, including SUBLOCADE, SUBOXONE Film/tablet, SUBUTEX Tablet, and INDV-2000 and INDV-6001 developments.
These are estimates and not guarantees; actual results depend on many factors. The forecast shows upside potential, but also inherent uncertainties in drug development, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
2030 avg $88.88; min $69.27; max $121.50; ROI 136.8; sentiment BULLISH.
The 2026 forecast is Neutral with avg $37.53 and max $53.19; later years show bullish momentum with rising averages and ROI.
Yes. The forecast shows 2031 min $77.77, avg $100.99, max $140.21, indicating upside beyond $100 in the 2031 period.
Current price is $37.53 and market cap is $4.44B.
Min $378.41, avg $572.71, max $938.28; ROI 1426; sentiment BULLISH.
Indivior Pharmaceuticals, Inc. Community Discussion
0Share your Indivior Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.